

Current report no. 25/2021

Drawn up on: 2021-03-16

Abbreviated name of issuer: MABION S.A.

Subject: Cancellation of the Extraordinary General Meeting of Mabion S.A. called for 22nd March 2021 and information on the review of the Company's financing strategy

Legal basis: Article 17(1) of MAR - confidential information

Contents of the report:

In reference to current report no. 3/2020 of 27th January 2021 on the adoption of financial strategy of Mabion S.A. (hereinafter referred to as the "Issuer", "Company") providing for two issues of the Company's shares, current report no. 11/2021 of 22nd February 2021 on convening an Extraordinary General Meeting ("EGM") of the Company on 22nd March 2021 in order to adopt a resolution on the latter above-mentioned issue, and current report no. 23/2021 of 15th March 2021 on the implementation of the former above-mentioned issue, i.e. the issue of series U shares, the Management Board of the Company informs about the decision taken on 16th March 2021 on the cancellation of the EGM of the Company which was to be held on 22nd March 2021 at 12:00 (noon) in Konstancin Łódzki, ul. Łąkowa 11 (Eureka Technology Park).

The decision of the Issuer's Management Board to cancel the EGM of the Company results from the need to review the current financial needs as a result, among others, of the successful issue of series U shares and the conclusion of a framework agreement along with the first order for contract services with Novavax, Inc. under the COVID-19 vaccination scheme (about which the Company informed in current report no. 15/2021 of 3rd March 2021).

The Issuer's Management Board notes that the acquisition of funds from the issue of series U shares and the conclusion of the agreement with Novavax Inc. enable potential access of the Company to additional (not fully available so far) sources of financing, including potential debt financing from Polish Development Fund S.A. (PLN 30 million), the granted and so far not used subsidy from the European Regional Development Fund (approx. PLN 63 million), and potentially to a credit from the European Investment Bank (up to the aggregate amount of EUR 30 million, i.e. approx. PLN 138 million) with which the Company is negotiating. In the current financing strategy, the Company has not taken into account the potential operating flows related to the co-operation with Novavax, Inc., which may bring additional operating flows to the Company provided that a specific scenario is followed (including the currently implemented initial stage, i.e. effective technology transfer, production of one technical batch and one testing batch, and then the next stage of continued co-operation on commercial terms).

Consequently, the decisions on updating the current financial strategy of the Company, including the decision whether or not to possibly carry out another issue of shares, referred to in section 3 of the above-mentioned report no. 3/2021, will be taken after detailed analyses with particular consideration of the factors mentioned above. The Company will inform about its decisions in a separate current report.